MelaFind comes a step closer to the US market with FDA approvable letter
This article was originally published in Clinica
Executive Summary
Mela Sciences' troubled melanoma detection device MelaFind finally looks likely to reach the US market after the company received an approvable letter from the FDA. The company must now agree a protocol with the agency for a post-approval study in order to obtain final approval, as well as finalising physician and patient labelling, the package insert, user's guide and training programme.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.